Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse | Annals of Internal Medicine

by Michelle Papp

March 13, 2019

Recent Posts

Pilot Grant Recipients Receive Funding to Examine Health Disparities Related to the Treatment of Substance Use Disorders, HCV, and HIV
July 27, 2021

Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use
July 26, 2021

Prescription Opioids Dispensed to Patients with Cancer with Bone Metastasis: 2011-2017
July 23, 2021

Hepatitis C Treatment by Non-specialist Providers in the Direct-acting Antiviral Era
June 28, 2021

Prescription Drug Monitoring Program Mandates Affect Use of Opioids to Treat Acute, Severe Pain
June 16, 2021